Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Total Liabilities (2017 - 2025)

Arcus Biosciences (RCUS) has 9 years of Total Liabilities data on record, last reported at $508.0 million in Q4 2025.

  • For Q4 2025, Total Liabilities changed N/A year-over-year to $508.0 million; the TTM value through Dec 2025 reached $508.0 million, changed N/A, while the annual FY2025 figure was $508.0 million, N/A changed from the prior year.
  • Total Liabilities reached $508.0 million in Q4 2025 per RCUS's latest filing, down from $538.0 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $750.4 million in Q4 2021 and bottomed at -$549.0 million in Q2 2025.
  • Average Total Liabilities over 5 years is $529.1 million, with a median of $633.0 million recorded in 2023.
  • Peak YoY movement for Total Liabilities: surged 661.36% in 2021, then tumbled 197.17% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $750.4 million in 2021, then fell by 14.32% to $643.0 million in 2022, then decreased by 1.56% to $633.0 million in 2023, then increased by 16.11% to $735.0 million in 2024, then plummeted by 30.88% to $508.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $508.0 million in Q4 2025, $538.0 million in Q3 2025, and -$549.0 million in Q2 2025.